TEL : 02-792-1486 / FAX : 02-792-1410 / E-mail : cancer@kams.or.kr
(As of February 27, 2018)
| Opening Remarks -Eun Kyung Choi (President of Korean Cancer Association) | 09:00-09:10 | |
| 1. | Recent trends in cancer immunology 1 | 09:10-10:30 |
| Chair: Sang-Jun Ha (Yonsei University College of Life Science and Biotechnology) | ||
| 1) | Iatrogenic immunosuppression in patients with cancer: Etiology, consequences, and approaches to preserve immune competence | |
| Stuart A. Grossman (Professor of Oncology, Medicine & Neurosurgery, the Johns Hopkins University School of Medicine) | ||
| 2) | Potential strategies to minimize treatment-related lymphopenia | |
| Jian Li Campian (Assistant Professor of Medicine, Washington University School of Medicine) | ||
| Break | 10:30-10:50 | |
| 2. | Recent trends in cancer immunology 2 | 10:50-12:00 |
| Chair: Tae You Kim (Seoul National University College of Medicine) | ||
| 1) | What happens to CD8+ T cells upon anti-PD-1 therapy? | |
| Eui-Cheol Shin (KAIST Endowed Chair Professor, Graduate School of Medical Science and Engineering, KAIST) | ||
| 2) | IL-7 in mice and humans: Beyond T cell homeostasis | |
| Ronald Eugene Gress (Chief, Experimental Transplantation and Immunology Branch, CCR, NCI) | ||
| Satellite Symposium (by MSD) | 12:00-13:00 | |
| Chair: Bong-Seog Kim (VHS Medical Center) | ||
| 1) | Immuno-oncologic strategy for head and neck cancer and urothelial carcinoma | |
| Bhumsuk Keam (Seoul National University College of Medicine) | ||
| 3. | Development of novel immunotherapeutics 1 | 13:00-14:40 |
| Chair: Yong Woo Jung (Korea University College of Pharmacy) | ||
| 1) | Targeting TGF-β: A key strategy to overcome resistance to immunotherapy | |
| John J. Letterio (Director, The Angie Fowler Adolescent & Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital & University Hospitals Cleveland Medical Center) | ||
| 2) | Development of tissue-agnostic immunotherapy utilizing stromal TGF-beta responsive gene signature (TBRS) | |
| Chan-Young Ock (Chief Medical Officer of Medpacto & Medical Director of Theragen Etex Bio) | ||
| 3) | Immunotherapy using vaccine: Neoantigen vs tumor associated Ag | |
| Kyong Hwa Park (Associate Professor, Department of internal medicine, College of medicine, Korea University) | ||
| Break | 14:40-15:00 | |
| 4. | Development of novel immunotherapeutics 2 | 15:00-16:50 |
| Chair: Yeul Hong Kim (Korea University College of Medicine) | ||
| 1) | Translating science into immuno-oncology therapies | |
| Jingwu Zang (Founder and CEO of I-MAB Biopharma) | ||
| 2) | A new antigen presenting cell based cancer therapeutic vaccine | |
| Chang-Yuil Kang (Professor, College of Pharmacy, Seoul National University) | ||
| 3) | Drivers in the clinical development of cancer combination therapy | |
| Emmett Vance Schmidt (Distinguished Scientist/Executive Director, Clinical Oncology, Merck Research Laboratories) | ||
| Closing | ||